![allogeneic stem cell transplant allogeneic stem cell transplant](https://basicmedicalkey.com/wp-content/uploads/2016/07/image07849.gif)
Wainwright MS, Martin PL, Morse RP, Lacaze M, Provenzale JM, Coleman RE et al.
![allogeneic stem cell transplant allogeneic stem cell transplant](https://image.slidesharecdn.com/currentperspectivesonstemcellbiologykotpphaseilecturedec242010-110103092723-phpapp02/95/current-perspectives-on-stem-cell-biology-67-728.jpg)
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen- Chaetomium atrobrunneum: case report. Guppy KH, Thomas C, Thomas K, Anderson D. Cytomegalovirus encephalitis occurring after bone marrow transplantation. Clin Neuropharmacol 1999 22: 67–73.Ĭordonnier C, Feuilhade F, Vernant JP, Marsault C, Rodet M, Rochant H. Cyclosporine A neurotoxicity among bone marrow transplant recipients. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Woo M, Przepiorka D, Ippoliti C, Warkentin D, Khouri I, Fritsche H et al. Bone Marrow Transplant 1991 8: 393–401.Įidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M, Jain A et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Reece DE, Frei-Lahr DA, Shepherd JD, Dorovini-Zis K, Gascoyne RD, Graeb DA et al. Neurologic complications of transplantation. Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. Maffini E, Festuccia M, Brunello L, Boccadoro M, Giaccone L, Bruno B. Neurological complications of transplantation: part I: hematopoietic cell transplantation. Neurological complications of hematopoietic cell transplantation. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 2011 29: 805–813. Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK et al. NCs after HCT are associated with poor outcomes, and usually occur early after HCT.
![allogeneic stem cell transplant allogeneic stem cell transplant](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2006/nejm_2006.354.issue-17/nejmra052638/production/images/img_medium/nejmra052638_f2.jpeg)
Risk factors for CNSC were age (hazard ratio (HR)=1.06 per year, P=0.0034), development of acute GvHD grade III–IV (HR=2.78, P=0.041), transfusion-dependent thrombocytopenia (HR=3.07, P=0.025) and delayed platelet engraftment (>90th centile HR=2.77, P=0.043). The 1- and 5-year cumulative incidences of all NCs were 15.6% and 19.2%, respectively, and of CNS complication (CNSC all of the above complications except peripheral neuropathy) were 12.2 and 14.5%. In all, 50 patients experienced 63 NCs-37 early ( ⩽day +100), 21 late (day +101 to 2 years) and 5 very late (2 to 5 years). We determined the incidence of central nervous system (CNS) infection, intracranial hemorrhage, ischemic stroke, metabolic encephalopathy, posterior reversal encephalopathy syndrome, seizure and peripheral neuropathy. We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of NCs in the first 5 years after HCT. Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT).